Dianthus Therapeutics (DNTH) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing a portfolio of autoimmune therapeutics with neuromuscular and rheumatology franchises, targeting best-in-disease, pipeline-in-a-product potential and patient-friendly, infrequent subcutaneous self-administration.

• Claseprubart leads the neuromuscular franchise, showing strong efficacy and safety in gMG, CIDP, and MMN, with multiple late-stage clinical milestones expected through 2028.

• DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, targets both innate and adaptive immune systems for enhanced efficacy in Sjögren's Disease, SLE, and Dermatomyositis, with Phase 1 data expected by year-end 2026.

• DNTH312, a next-generation fusion protein combining claseprubart and TACI, aims to expand leadership across severe autoimmune diseases, with Phase 1 readiness targeted by year-end 2027.

• Strong financial position with ~$1.2B in cash and runway expected into 2030 to fund multiple near- and long-term catalysts.

Clinical data and market opportunity

• Claseprubart demonstrated rapid, sustained, and statistically significant improvements in key efficacy measures (MG-ADL, QMG, MGC, MG-QOL-15r) in gMG, with a favorable safety profile and no boxed warning or REMS.

• In CIDP, a 75% response rate was observed in the CAPTIVATE Part A interim analysis, supporting best-in-disease potential and continued development.

• MMN market opportunity is significant, with robust clinical proof-of-concept for classical pathway inhibition and superior in vitro potency versus competitors.

• DNTH212 shows superior in vitro pDC depletion and Ig inhibition compared to litifilimab and povetacicept, supporting its potential as a best-in-class therapy for multiple autoimmune diseases.

• Surveys of US neurologists confirm high unmet need and preference for safer, more effective, and convenient therapies across gMG, CIDP, and MMN.

Competitive differentiation and innovation

• Claseprubart targets upstream complement inhibition, potentially offering improved efficacy and safety over C5 inhibitors, with convenient self-administration via autoinjector.

• DNTH212 and DNTH312 leverage dual-mechanism approaches to address both innate and adaptive immune pathways, aiming for superior efficacy and broader disease coverage.

• The company’s pipeline is protected by robust intellectual property, with composition of matter patents extending into the 2040s.

• Leadership team comprises experienced biotech executives with a track record of developing and commercializing leading autoimmune therapies.

• Multiple upcoming clinical milestones across programs, including Phase 3 and Phase 2 data readouts, position the company for significant value inflection points.